Literature DB >> 27487002

Association between X-Ray Repair Cross-Complementing Group 1 Arg399Gln Polymorphism and Cervical Cancer Risk: A Meta-Analysis in the Chinese Population.

Fang Zhang1, Bing Li, Hong-Yan Wu, Li-Xin Shang.   

Abstract

BACKGROUND: Many studies have examined the association of X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln polymorphism with cervical cancer susceptibility. However, the results of these studies are inconsistent. To further assess the effects of XRCC1 Arg399Gln polymorphism on the risk of cervical cancer in the Chinese population, a meta-analysis was performed.
METHODS: Relevant studies were identified using PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure, and Chinese Biology Medicine through December 2015. Pooled ORs and 95% CIs were used to assess the strength of the associations.
RESULTS: This meta-analysis identified 7 studies, including 1,589 cases and 2,235 controls. In the total analyses, a significantly elevated risk of cervical cancer was associated with variants of XRCC1 Arg399Gln (GA vs. GG: OR 1.30, 95% CI 1.13-1.49; AA + GA vs. GG: OR 1.27, 95% CI 1.02-1.58). In the subgroup analyses stratified by geographic areas and histopathology type, it revealed the significant result in South China.
CONCLUSIONS: This meta-analysis showed that the XRCC1 Arg399Gln GA variant might be risk alleles for cervical cancer susceptibility in the Chinese population, and further studies in other ethnic groups are required to arrive at definite conclusions.
© 2016 S. Karger AG, Basel.

Entities:  

Keywords:  Cervical cancer; Meta-analysis; Polymorphism; X-ray repair cross-complementing group 1

Mesh:

Substances:

Year:  2016        PMID: 27487002     DOI: 10.1159/000448142

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

1.  Association between XRCC1 polymorphisms and the risk of cervical cancer: a meta-analysis based on 4895 subjects.

Authors:  Xianling Zeng; Yafei Zhang; Ting Yue; Taohong Zhang; Junxia Wang; Yan Xue; Ruifang An
Journal:  Oncotarget       Date:  2017-01-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.